ICH E3 section 12.4 calls for evaluation of laboratory data with attention to values over time, individual patient changes, and clinically significant abnormalities. The required detail depends on the study and reviewing authority; do not treat every laboratory measurement as equally important or duplicate raw listings in narrative form.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
The CSR laboratory-data section summarizes and analyzes laboratory findings so clinically important patterns, changes, and abnormalities can be evaluated.
Key details
Core IssueICH E3 section 12.4 calls for evaluation of laboratory data with attention to values over time, individual patient changes, and clinically significant abnormalities.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
The required detail depends on the study and reviewing authority; do not treat every laboratory measurement as equally important or duplicate raw listings in narrative form.
Further guidance
Content
Present appropriate summary analyses and patient-level changes, identify clinically significant abnormalities, and discuss their possible relationship to treatment, dose, patient factors, and concomitant therapy where relevant.
Purpose
The CSR laboratory-data section summarizes and analyzes laboratory findings so clinically important patterns, changes, and abnormalities can be evaluated.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 section 9.6 calls for data quality assurance information relevant to the reliability and integrity of the reported study data. This CSR-specific section does not replace broader trial quality-management guidance and should not be conflated with the separate appendix for interlaboratory standardization documentation.
ICH E3 section 11.1 calls for the exact patients included in each efficacy analysis to be precisely defined and for relevant exclusions and their timing or rationale to be accounted for. This CSR subsection reports the sets actually analyzed; it is distinct from protocol-stage prespecification of analysis populations and from general study-population selection criteria.
ICH E3 calls for demographic and other baseline characteristics in the core efficacy evaluation and also identifies patient-level demographic data among the report’s appendix listings. This page is specific to ICH E3 clinical-study-report presentation and is distinct from general manuscript advice about a baseline-characteristics table.
ICH E3 section 12.4.2 calls for evaluation of each laboratory parameter, with treatment and control groups compared as appropriate and normal laboratory ranges supplied for each analysis. This is the analytical layer under ICH E3 12.4.2; it is distinct from the patient-level raw/listing appendix and from a generic laboratory-data overview.
ICH E3 section 11.4.2.2 calls for the methods used to address dropouts and missing observations in efficacy analysis to be described and justified. This is the CSR results-analysis treatment of missing efficacy data; it does not replace the broader protocol or statistical-analysis-plan description of prespecified methods.
ICH E3 appendix 16.2.6 designates individual efficacy response data as a patient-level listing in the clinical study report supporting material. This is a patient-level listing function, not a substitute for aggregate efficacy tables, statistical analyses, or the broader individual-patient-data appendix overview.
ICH E3 appendix 16.2.8 addresses listings of individual laboratory measurements by patient when such listings are required by regulatory authorities. ICH E3 makes these patient-level listings conditional on regulatory requirements; this page does not imply that every CSR must include the same laboratory appendix.
